Synthaverse S.A.

WSE:SVE Stock Report

Market Cap: zł213.0m

Synthaverse Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Synthaverse.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth22.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article May 20

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is Lacking

Synthaverse S.A. ( WSE:SVE ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
Analysis Article Nov 28

Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Synthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...
Analysis Article Apr 20

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Synthaverse S.A. ( WSE:SVE ) shareholders would be excited to see that the share price has had a great month, posting a...
Analysis Article Apr 18

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

The market shrugged off Synthaverse S.A.'s ( WSE:SVE ) weak earnings report. Despite the market responding positively...
Analysis Article Oct 14

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Nov 29

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) shareholders that were waiting for something to happen...
Analysis Article Nov 16

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s ( WSE:BML ) robust recent earnings didn't do much to move the...
Analysis Article May 02

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article Mar 08

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Jan 29

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Every investor in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) should be aware of the most powerful...
Analysis Article Jan 03

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

With its stock down 49% over the past three months, it is easy to disregard BIOMED-LUBLIN Wytwórnia Surowic i...
Analysis Article Dec 07

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Synthaverse has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

WSE:SVE - Analysts future estimates and past financials data (PLN Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202542-20-1612N/A
9/30/2024634-5815N/A
6/30/2024572-1026N/A
3/31/2024614-1181N/A
12/31/2023595-118-5N/A
9/30/2023533-97-6N/A
6/30/2023587-68-2N/A
3/31/2023547-432N/A
12/31/2022506-343N/A
9/30/2022517-300N/A
6/30/2022444-26-6N/A
3/31/2022445-19-4N/A
12/31/2021414-22-3N/A
9/30/2021395-111N/A
6/30/2021405-14N/A
3/31/2021352-40N/A
12/31/2020404-20N/A
9/30/2020412-4-2N/A
6/30/202040334N/A
3/31/202040345N/A
12/31/201939278N/A
9/30/201935-29N/A10N/A
6/30/201936-31N/A3N/A
3/31/201935-32N/A7N/A
12/31/201832-32N/A-1N/A
9/30/20183110N/A-5N/A
6/30/20183111N/A-2N/A
3/31/2018301N/A-2N/A
12/31/2017311N/A4N/A
9/30/201731-23N/A31N/A
6/30/201732-27N/A30N/A
3/31/201737-26N/A10N/A
12/31/201636-26N/A16N/A
9/30/201646-48N/A-4N/A
6/30/201645-45N/A-15N/A
3/31/201647-35N/A5N/A
12/31/201543-37N/A-3N/A
9/30/201538-2N/A-5N/A
6/30/201536-2N/A2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SVE's forecast earnings growth is above the savings rate (5.3%).

Earnings vs Market: Insufficient data to determine if SVE's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if SVE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SVE's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if SVE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SVE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 16:41
End of Day Share Price 2026/05/21 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Synthaverse S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.